Background
S.A.S.B. Corp., which operates Okeechobee Discount Drugs in Florida, alleged that Johnson & Johnson Health Care Systems and Janssen Pharmaceuticals sent an unsolicited two-page fax to its pharmacy. The fax described Janssen CarePath, a patient-support program offering resources and savings options for Xarelto, an anticoagulant drug sold by Janssen.
SASB alleged that CarePath’s cost assistance made Xarelto more competitive with less-expensive alternatives, including generic Warfarin. It brought a putative class action under the Telephone Consumer Protection Act, which prohibits sending unsolicited advertisements by fax. The District of New Jersey dismissed the amended complaint, concluding that the fax was not an advertisement.
The Court’s Holding
The Third Circuit reversed. Taking the allegations as true, a reasonable factfinder could determine that the fax promoted Xarelto with profit as its aim. Its promises to help recipients lower out-of-pocket costs and find programs to pay for Xarelto plausibly promoted the drug by emphasizing affordability, much like a coupon promotes a product through a discount.
The court held that the fax had to be assessed as a whole. Although the second page included informational material about Xarelto’s uses and side effects, defendants could not avoid TCPA liability by attaching informational content to an unsolicited advertisement. The court also held that SASB plausibly alleged the defendants sent the fax and gave both subsidiaries adequate notice of the conduct alleged, even though discovery was needed to determine their respective roles.
Key Takeaways
- A fax promoting financial assistance for a prescription drug can qualify as a TCPA advertisement when it plausibly encourages purchase of that drug.
- Informational material accompanying promotional content does not necessarily remove a fax from the TCPA’s coverage.
- At the pleading stage, a plaintiff need not establish the most likely sender or precisely divide responsibility among related defendants when that information is within their possession.
Why It Matters
The decision confirms that promotional messaging need not use overt sales language to be an advertisement under the TCPA. Communications framing themselves as patient support may still be actionable if they plausibly market a product by reducing perceived cost barriers.
It also reinforces the Third Circuit’s application of ordinary Rule 8 pleading standards in TCPA fax cases, allowing plaintiffs to pursue discovery where sender identity and corporate responsibility are not publicly available.